Emyria Limited (ASX:EMD) has opened the Empax Centre, a cutting-edge facility designed to advance mental health treatments, including psychedelic-assisted therapies, with a focus on PTSD sufferers.
This state-of-the-art technology hub will boost Emyria’s clinical capabilities, particularly in addressing conditions such as Post-Traumatic Stress Disorder (PTSD).
“The Empax Centre demonstrates Emyria’s commitment to lead the way in mental health innovation within the regulatory frameworks set by the TGA,” Emyria CEO Dr. Michael Winlo said.
“Our extensive research and development efforts, particularly in MDMA-assisted therapy for PTSD, have shaped our strategic approach towards scalability and profitability – essential for the widespread adoption and success of these innovative treatments.”
“The Empax Centre not only signifies our commitment to improving mental health care but also highlights our firm belief in the transformative potential of our treatments.”
The primary aim of the Empax Centre is to cater to individuals struggling with resistant forms of PTSD, including frontline responders. With an estimated one million Australians affected by PTSD, and many not responding to conventional treatments, the Centre aims to bridge this gap through new treatment and research.
Led by industry pioneers and supported by a team of over 14 clinicians trained in psychedelic-assisted therapy, the Empax Centre ensures patient comfort and safety during extended sessions. Advanced audio-visual monitoring and an AI-generated music system to further enhance the therapeutic experience.
The centre is projected to achieve operating break-even by the second half of 2024, and is expected to generate revenue from direct patient care and sponsored clinical research.
Plans for additional centres are already in progress, underscoring Emyria’s commitment to advancing mental health care.
EMD shares were holding steady and last traded at 6.3c.